The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives
Open Access
- 15 October 2021
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 9 (10) , 1481
Abstract
Rare ovarian cancers are ovarian cancers with an annual incidence of less than 6 cases per 100,000 women. They generally have a poor prognosis due to being delayed diagnosis and treatment. Exploration of molecular mechanisms in these cancers has been challenging due to their rarity and research efforts being fragmented across the world. Omics approaches can provide detailed molecular snapshots of the underlying mechanisms of these cancers. Omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, can identify potential candidate biomarkers for diagnosis, prognosis, and screening of rare gynecological cancers and can aid in identifying therapeutic targets. The integration of multiple omics techniques using approaches such as proteogenomics can provide a detailed understanding of the molecular mechanisms of carcinogenesis and cancer progression. Further, omics approaches can provide clues towards developing immunotherapies, cancer recurrence, and drug resistance in tumors; and form a platform for personalized medicine. The current review focuses on the application of omics approaches and integrative biology to gain a better understanding of rare ovarian cancers.Keywords
This publication has 111 references indexed in Scilit:
- Recent progress using systems biology approaches to better understand molecular mechanisms of immunitySeminars in Immunology, 2012
- Metabolomics: the apogee of the omics trilogyNature Reviews Molecular Cell Biology, 2012
- Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platformActa Oncologica, 2012
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigmHuman Pathology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010
- Management of rare ovarian cancers: The experience of the French website «Observatory for rare malignant tumours of the ovaries» by the GINECO group: Interim analysis of the first 100 patientsGynecologic Oncology, 2010
- mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the OvaryClinical Cancer Research, 2009
- Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic ProfilingJournal of Proteome Research, 2007
- Chemotherapy for ovarian germ cell tumoursEuropean Journal of Cancer, 1996